The first domestic gene detector in the United States has been approved to be listed or opened the new trend of DIY disease detection
the U.S. Food and Drug Administration (FDA) recently announced that it allows the start-up company 23 me to directly sell its gene detector to consumers. The device can simultaneously detect Alzheimer's disease, Parkinson's syndrome and other futures. The iron ore 1609 contract surged throughout the day to reduce the genetic risk of 10 diseases with weak vibration. This long-awaited decision marks the official approval of the first domestic gene testing equipment to go on the market, which will create a new trend of DIY disease detection
23 me said that they would provide this new service as soon as possible in the next few months. "This is a watershed for our company and FDA," said Keith Hibbs, the company's chief regulatory officer Since 2006, consumers have sent e-mails to the company asking for hair color and other services. 2. The company has also provided a DNA detection device that can detect 240 health conditions at one time, but it was urgently stopped by FDA in 2013. Because the accuracy of its test results cannot be determined by the existing change experiments, which can only record the number of twisting and breaking turns and other semi quantitative indicators, FDA is worried that consumers will decide the medication plan at home only by relying on the company's test information, which may cause serious consequences
in 2015, FDA relaxed the restrictions and allowed the company to provide testing services to prospective parents with genetic defects. However, it can only detect whether their children carry one of the 36 serious genetic genes, and cannot detect the disease risk of the prospective parents themselves
this time, FDA gave the company a green light, allowing it to directly provide consumers with testing equipment, which can detect strongly related gene mutations of 10 diseases including Parkinson's syndrome, Alzheimer's disease, lipodiarrhea and thrombosis at one time. Insiders welcome this. Hank Greeley, a bioethicist at Stanford University, said, "this shows that the cooperation between gene testing companies and FDA has taken a big step forward. Silicon Valley companies have long had a tense relationship with FDA, and believe that the strict regulations of FDA are not conducive to the development of the health industry that is vital to life"
Greely believes that other companies will follow up and provide similar services, and 23 me will gradually expand the diseases involved in genetic testing. However, this kind of test is not equivalent to medical diagnosis. Besides genetic variation, lifestyle, family history and environment will bring about disease risks. Consumers' own cognition of test results is limited. They should timely inform doctors of the test results at home for help